US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Neuroscience Inc

14.27

-0.0500-0.35%

Volume:389.15K

Turnover:5.52M

Market Cap:441.07M

PE:-5.94

High:14.70

Open:14.31

Low:13.54

Close:14.32

52wk High:15.18

52wk Low:1.60

Shares:30.91M

Float Shares:17.88M

Volume Ratio:0.45

T/O Rate:2.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4043

EPS(LYR):-2.4970

ROE:-42.78%

ROA:-24.72%

PB:3.57

PE(LYR):-5.71

Loading ...

Overview Company News Filings

Alto Neuroscience Q2 EPS $(0.65) Misses $(0.61) Estimate

Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026

Alto Neuroscience Inc - Cash to Fund Operations Into 2028

THOMSON REUTERS

Alto Neuroscience Inc - Q2 EPS $-0.65

THOMSON REUTERS

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.d., to Its Board of Directors

THOMSON REUTERS

Shareholders File Class Action Lawsuit Against Alto Neuroscience Inc. Over IPO Missteps

Alto Neuroscience Inc. Implements Option Repricing to Retain Talent Amid Underwater Stock Options

Alto Neuroscience Inc. Unveils Corporate Presentation on Precision Medicine for Psychiatry

Alto Neuroscience Announces Phase 2b Trial Launch of ALTO-207 for Treatment-Resistant Depression, Backed by New Lancet Psychiatry Study

Alto Neuroscience Inc. Unveils Presentation on Precision Medicine Advancements in Psychiatry

Alto Neuroscience Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Alto Neuroscience Announces Positive Results from Phase 2 Trial of ALTO-203, Highlighting Biomarker for Enhanced Attention in Major Depressive Disorder Patients

Alto Neuroscience Unveils Precision Medicine Strategy for Psychiatry in New Corporate Presentation

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Alto Neuroscience Acquires Dopamine Agonist Combination ALTO-207 to Enhance Treatment for Resistant Depression

Alto Neuroscience Inc. to Participate in Jefferies Global Healthcare Conference

Alto Neuroscience Price Target Maintained With a $4.00/Share by Wedbush

BRIEF-Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights

Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate

Alto Neuroscience Reports Q1 2025 Net Loss of $15.2 Million, Up from $13.4 Million in Q1 2024; Strong Cash Position Maintained

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANRO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience Inc","latestPrice":14.27,"timestamp":1761940706330,"preClose":14.32,"halted":0,"volume":389149,"delay":0,"floatShares":17884024,"shares":30908892,"eps":-2.404277,"marketStatus":"Trading","change":-0.05,"latestTime":"10-31 15:58:26 EDT","open":14.31,"high":14.7,"low":13.54,"amount":5520902.782582,"amplitude":0.081006,"askPrice":14.29,"askSize":100,"bidPrice":14.22,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-2.404277,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1761940800000},"marketStatusCode":2,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":14.32,"preHourTrading":{"tag":"盘前","latestPrice":14.54,"preClose":14.32,"latestTime":"09:17 EDT","volume":356,"amount":5228.970007999999,"timestamp":1761916668959},"postHourTrading":{"tag":"盘后","latestPrice":14.54,"preClose":14.32,"latestTime":"19:48 EDT","volume":6610,"amount":94842.25,"timestamp":1761868116531},"volumeRatio":0.453546,"impliedVol":1.0299,"impliedVolPercentile":0.176},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":17884024,"roa":"-24.72%","roe":"-42.78%","lyrEps":-2.496992,"volumeRatio":0.453546,"shares":30908892,"dividePrice":0,"high":14.7,"amplitude":0.081006,"preClose":14.32,"low":13.54,"week52Low":1.6,"pbRate":"3.57","week52High":15.18,"institutionHeld":0,"latestPrice":14.27,"committee":-0.851852,"eps":-2.404277,"divideRate":0,"volume":389149,"delay":0,"ttmEps":-2.404277,"open":14.31,"prevYearClose":4.23,"prevWeekClose":11,"prevMonthClose":4.02,"prevQuarterClose":4.02,"fiveDayClose":11,"twentyDayClose":6.89,"sixtyDayClose":3.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"ANRO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.65}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.4444,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4444,"analysts":9,"updateTime":1759204800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2025-10-30","current":-5.956052,"percent":0.358852,"low":-16.978804,"twenty":-7.815152,"median":-2.083968,"eighty":-1.28113,"high":-0.793245,"avg":-4.515391,"sd":3.931719,"marketCap":380155871},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290},{"date":"2025-04-25","current":-1.004777,"twenty":-10.431438,"median":-6.11117,"eighty":-1.798105,"marketCap":61724454},{"date":"2025-05-02","current":-1.079695,"twenty":-10.421079,"median":-6.037568,"eighty":-1.742706,"marketCap":66326716},{"date":"2025-05-09","current":-0.965115,"twenty":-10.40924,"median":-5.975847,"eighty":-1.645994,"marketCap":59287962},{"date":"2025-05-16","current":-1.041186,"twenty":-10.323409,"median":-5.766106,"eighty":-1.583083,"marketCap":65785273},{"date":"2025-05-23","current":-1.255422,"twenty":-10.270134,"median":-5.686944,"eighty":-1.500455,"marketCap":79321337},{"date":"2025-05-30","current":-1.152589,"twenty":-10.199102,"median":-5.617282,"eighty":-1.480737,"marketCap":72824027},{"date":"2025-06-06","current":-1.019763,"twenty":-10.071835,"median":-5.469741,"eighty":-1.461958,"marketCap":64431667},{"date":"2025-06-13","current":-1.049756,"twenty":-10.02004,"median":-5.30697,"eighty":-1.408438,"marketCap":66326716},{"date":"2025-06-20","current":-0.972631,"twenty":-9.987484,"median":-5.077305,"eighty":-1.322054,"marketCap":61453732},{"date":"2025-06-27","current":-0.985485,"twenty":-9.980084,"median":-2.492642,"eighty":-1.263991,"marketCap":62265896},{"date":"2025-07-03","current":-1.006909,"twenty":-9.974165,"median":-2.341082,"eighty":-1.221144,"marketCap":63619503},{"date":"2025-07-11","current":-1.105457,"twenty":-9.589405,"median":-2.272279,"eighty":-1.163435,"marketCap":69846092},{"date":"2025-07-18","current":-1.233999,"twenty":-8.963166,"median":-2.213594,"eighty":-1.13545,"marketCap":77967731},{"date":"2025-07-25","current":-1.319693,"twenty":-8.840728,"median":-2.178383,"eighty":-1.148304,"marketCap":83382157},{"date":"2025-08-01","current":-1.315408,"twenty":-8.760609,"median":-2.161951,"eighty":-1.152589,"marketCap":83111436},{"date":"2025-08-08","current":-1.311123,"twenty":-8.486086,"median":-2.154336,"eighty":-1.163435,"marketCap":82840714},{"date":"2025-08-15","current":-1.302504,"twenty":-8.327763,"median":-2.124393,"eighty":-1.163435,"marketCap":84479082},{"date":"2025-08-22","current":-1.498714,"twenty":-8.182106,"median":-2.122046,"eighty":-1.165443,"marketCap":97205098},{"date":"2025-08-29","current":-1.590557,"twenty":-8.114957,"median":-2.098572,"eighty":-1.169728,"marketCap":103161956},{"date":"2025-09-05","current":-1.465317,"twenty":-8.049126,"median":-2.084227,"eighty":-1.178742,"marketCap":95038967},{"date":"2025-09-12","current":-1.640654,"twenty":-7.979964,"median":-2.075098,"eighty":-1.18912,"marketCap":106411151},{"date":"2025-09-19","current":-1.715798,"twenty":-7.951589,"median":-2.070403,"eighty":-1.198007,"marketCap":111284945},{"date":"2025-09-26","current":-1.586383,"twenty":-7.904286,"median":-2.056319,"eighty":-1.216859,"marketCap":102891190},{"date":"2025-10-03","current":-1.841039,"twenty":-7.881184,"median":-2.039887,"eighty":-1.228,"marketCap":119407933},{"date":"2025-10-10","current":-2.513164,"twenty":-7.867586,"median":-2.056319,"eighty":-1.233142,"marketCap":163001306},{"date":"2025-10-17","current":-2.454718,"twenty":-7.85227,"median":-2.070403,"eighty":-1.244282,"marketCap":159210578},{"date":"2025-10-24","current":-4.667305,"twenty":-7.827138,"median":-2.075098,"eighty":-1.253708,"marketCap":302716712},{"date":"2025-10-30","current":-5.861266,"twenty":-7.815152,"median":-2.083968,"eighty":-1.28113,"marketCap":380155871}],"updateTime":1761903428661},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559981312","title":"Alto Neuroscience Q2 EPS $(0.65) Misses $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981312","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981312?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:25","pubTimestamp":1755116737,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.61) by 7.08 percent. This is a 8.33 percent decrease over losses of $(0.60) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47106893/alto-neuroscience-q2-eps-0-65-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alto Neuroscience Q2 EPS $(0.65) Misses $(0.61) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2559892589","title":"Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2559892589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559892589?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:12","pubTimestamp":1755115930,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLb2G0Xr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2559981840","title":"Alto Neuroscience Inc -  Cash to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2559981840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559981840?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:10","pubTimestamp":1755115800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUA4QNPMF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2559863981","title":"Alto Neuroscience Inc - Q2 EPS $-0.65","url":"https://stock-news.laohu8.com/highlight/detail?id=2559863981","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559863981?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:10","pubTimestamp":1755115800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUA4QNPMF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2559565604","title":"Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.d., to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2559565604","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559565604?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:03","pubTimestamp":1755086580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nTUAFRNWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2559626146","title":"Shareholders File Class Action Lawsuit Against Alto Neuroscience Inc. Over IPO Missteps","url":"https://stock-news.laohu8.com/highlight/detail?id=2559626146","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559626146?lang=en_us&edition=fundamental","pubTime":"2025-08-13 02:47","pubTimestamp":1755024436,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Alto Neuroscience Inc. on behalf of individuals and entities that purchased Alto common stock connected to the company's initial public offering around February 2, 2024, as well as those who acquired Alto securities between February 2, 2024, and October 22, 2024. The lawsuit alleges that the company's offering documents contained inaccuracies that may have misled investors. Shareholders who experienced losses during this period are encouraged to seek legal counsel. Levi & Korsinsky, a law firm with significant experience in securities litigation, is representing the plaintiffs in this case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL9SyD6H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2550575653","title":"Alto Neuroscience Inc. Implements Option Repricing to Retain Talent Amid Underwater Stock Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2550575653","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550575653?lang=en_us&edition=fundamental","pubTime":"2025-07-09 05:19","pubTimestamp":1752009571,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. announced a repricing of certain stock options for its employees and consultants, effective July 3, 2025. The repricing applies to options granted under the company's 2019 and 2024 Equity Incentive Plans, specifically targeting options with exercise prices over $2.35 per share. This move affects options held by key executives, including CEO Dr. Amit Etkin, CFO Nicholas Smith, and COO Michael Hanley. The repricing initiative impacts a total of 4,225,763 shares, with the aim to adjust the exercise prices of options that are currently \"underwater,\" meaning their exercise prices exceed the current market value of the company's stock. The new terms require participants to remain with the company through a specified Retention Period to exercise the options at the reduced price.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLbMfRn4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2547091628","title":"Alto Neuroscience Inc. Unveils Corporate Presentation on Precision Medicine for Psychiatry","url":"https://stock-news.laohu8.com/highlight/detail?id=2547091628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547091628?lang=en_us&edition=fundamental","pubTime":"2025-06-30 20:31","pubTimestamp":1751286704,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has released a corporate presentation highlighting its advancements in precision medicine for the brain. The company, listed on the NYSE under the ticker ANRO, is focused on redefining psychiatry by utilizing individuals' neurobiology to develop personalized medicines. The presentation outlines the company's clinical-stage precision medicine portfolio, noting that over 800 patients have been dosed across studies with Alto's novel product candidates. The company anticipates several Phase 2 data readouts in the next two years and discusses the potential patient impact and opportunity across its portfolio. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDLV2LRw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2547099615","title":"Alto Neuroscience Announces Phase 2b Trial Launch of ALTO-207 for Treatment-Resistant Depression, Backed by New Lancet Psychiatry Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2547099615","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547099615?lang=en_us&edition=fundamental","pubTime":"2025-06-30 20:03","pubTimestamp":1751284998,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Announces Phase 2b Trial Launch of ALTO-207 for Treatment-Resistant Depression, Backed by New Lancet Psychiatry Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on June 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL3t9QsK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2546729515","title":"Alto Neuroscience Inc. Unveils Presentation on Precision Medicine Advancements in Psychiatry","url":"https://stock-news.laohu8.com/highlight/detail?id=2546729515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546729515?lang=en_us&edition=fundamental","pubTime":"2025-06-28 03:56","pubTimestamp":1751054198,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc., listed on NYSE under the ticker ANRO, has released a corporate presentation detailing its advancements in precision medicine for the brain. The company is focused on leveraging predictive biomarkers and target specificity to enhance clinical outcomes in central nervous system  disorders. Alto Neuroscience is progressing with a clinical-stage portfolio, having dosed over 800 patients with its novel product candidates. The company anticipates multiple phase 2 data readouts in the next two years and highlights its expected cash runway. Alto positions CNS as the next frontier in precision medicine, alongside fields like oncology and cardiovascular health. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL5mr12H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2546300547","title":"Alto Neuroscience Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2546300547","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546300547?lang=en_us&edition=fundamental","pubTime":"2025-06-27 00:26","pubTimestamp":1750955160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 12:26 ET (16:26 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2546358787","title":"Alto Neuroscience Announces Positive Results from Phase 2 Trial of ALTO-203, Highlighting Biomarker for Enhanced Attention in Major Depressive Disorder Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2546358787","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546358787?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:33","pubTimestamp":1750937601,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Announces Positive Results from Phase 2 Trial of ALTO-203, Highlighting Biomarker for Enhanced Attention in Major Depressive Disorder Patients. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on June 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL1FrZ35:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2543680664","title":"Alto Neuroscience Unveils Precision Medicine Strategy for Psychiatry in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2543680664","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543680664?lang=en_us&edition=fundamental","pubTime":"2025-06-13 21:41","pubTimestamp":1749822118,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has released a corporate presentation detailing its progress in the field of precision medicine for the brain. The presentation highlights Alto's clinical-stage precision medicine portfolio, which aims to redefine psychiatry by using neurobiology to develop personalized medicines. With over 800 patients dosed across studies, Alto is advancing its novel product candidates and precision approach. The presentation also notes the company's focus on CNS as the next frontier in precision medicine, drawing parallels with advancements in oncology and cardiovascular fields. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL5kWSyZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2540709879","title":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2540709879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540709879?lang=en_us&edition=fundamental","pubTime":"2025-06-04 01:42","pubTimestamp":1748972559,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture GlobalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nL6N3S60GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","BK4015","VG","CVX","WWD","DVN","STR","IE00BGHQF524.EUR","DG","OSK","XYZ","LU2290526834.HKD","SG9999001143.SGD","IE00BD4GTW91.USD","ANRO","SCCO","BMBL","HPE","LU2125154778.USD","XOM","AGEN","PINS","GH","LU2211817866.USD","SIG","LU1951198990.SGD","KYMR","LU1978683503.SGD","NEM","BEAM","LU0985489474.SGD","FCX","STRK","LU1064131342.USD","LIF","FDX","LU2286300806.USD"],"gpt_icon":1},{"id":"2540094720","title":"Alto Neuroscience Acquires Dopamine Agonist Combination ALTO-207 to Enhance Treatment for Resistant Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2540094720","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540094720?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:03","pubTimestamp":1748945002,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company, announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation. This includes ALTO-207, formerly known as CTC-501, aimed at treating treatment-resistant depression . The acquisition aligns with Alto's mission to innovate in psychiatry by advancing ALTO-207, which combines pramipexole and ondansetron to deliver rapid antidepressant effects while minimizing adverse events. Alto plans to leverage its proprietary insights on dopamine biomarkers to further develop this promising treatment, with a Phase 2b trial anticipated by mid-2026. The transaction supports Alto's strategic expansion without altering its cash runway guidance into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDLtgrWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2538730074","title":"Alto Neuroscience Inc. to Participate in Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2538730074","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538730074?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:03","pubTimestamp":1748433792,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc., a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders, is set to participate in the Jefferies Global Healthcare Conference from June 3-5, 2025. The company's management team will engage in a fireside chat and hold one-on-one investor meetings, with their presentation scheduled for June 5, 2025, at 2:00 pm ET at the New York Marriott Marquis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL9FmdBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2535582780","title":"Alto Neuroscience Price Target Maintained With a $4.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2535582780","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535582780?lang=en_us&edition=fundamental","pubTime":"2025-05-15 22:58","pubTimestamp":1747321080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 10:58 ET (14:58 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2535883067","title":"BRIEF-Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535883067","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535883067?lang=en_us&edition=fundamental","pubTime":"2025-05-15 05:21","pubTimestamp":1747257687,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Reports First Quarter 2025 Financial Results And Recent Business HighlightsMay 14 (Reuters) - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE REPORTS FIRST QUARTER 2025 FINANCIA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA2YJQ4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2535800700","title":"Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535800700","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535800700?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:25","pubTimestamp":1747254357,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.61) by 8.2 percent. This is a 26.32 percent increase over losses of $(0.76) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421050/alto-neuroscience-q1-eps-0-56-beats-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2535429007","title":"Alto Neuroscience Reports Q1 2025 Net Loss of $15.2 Million, Up from $13.4 Million in Q1 2024; Strong Cash Position Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2535429007","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535429007?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:19","pubTimestamp":1747253958,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Reports Q1 2025 Net Loss of $15.2 Million, Up from $13.4 Million in Q1 2024; Strong Cash Position Maintained. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDLWXgdr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":61,"code":"91000000","status":"200"}]}}